Are Spin-Outs Really a Better Bet?

01 Oct 2004

• By Melanie Senior

Big Pharma spin-outs may on average have raised 50% more private money than non-spin-outs over the last five years, but it's not yet clear whether they always deliver better returns on investment. Still, spin-outs remain an investor favorite, and in Europe are becoming the mainstay of a sustainable biopharma industry.

By Melanie Senior

The advantages of Big Pharma spin-outs are well documented. Emerging from larger, typically well-funded groups, spin-outs usually come complete with...